Cargando…

Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens

It is hypothesized that SARS-CoV-2 has the potential to elicit autoimmunity due to molecular mimicry between immunogenic proteins of the virus and human extracellular molecules. While in silico and in vitro evaluation of such immune cross-reactivity of human antibodies to SARS-CoV-2 proteins with se...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasperkiewicz, Michael, Bednarek, Marta, Tukaj, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720918/
https://www.ncbi.nlm.nih.gov/pubmed/34988105
http://dx.doi.org/10.3389/fmed.2021.807711
_version_ 1784625227580309504
author Kasperkiewicz, Michael
Bednarek, Marta
Tukaj, Stefan
author_facet Kasperkiewicz, Michael
Bednarek, Marta
Tukaj, Stefan
author_sort Kasperkiewicz, Michael
collection PubMed
description It is hypothesized that SARS-CoV-2 has the potential to elicit autoimmunity due to molecular mimicry between immunogenic proteins of the virus and human extracellular molecules. While in silico and in vitro evaluation of such immune cross-reactivity of human antibodies to SARS-CoV-2 proteins with several different tissue antigens has been described, there is limited information specifically pertaining to the immunological effects of COVID-19 and vaccines against SARS-CoV-2 on the development of autoimmune bullous diseases (AIBDs). Twelve seropositive post-COVID-19 individuals and 12 seropositive healthy volunteers who received two doses of the mRNA COVID-19 vaccine from Pfizer-BioNTech have been included in this case series investigation. Serum samples of these blood donors were tested for autoantibodies to the main immunobullous autoantigens, i.e., desmoglein 1, desmoglein 3, envoplakin, BP180, BP230, and type VII collagen. Our study revealed that none of the 24 anti-SARS-CoV-2 IgG-positive subjects had concomitant antibody reactivity with any of the tested autoantigens. These results argue against a relationship between SARS-CoV-2 infection/vaccines and AIBDs with respect to disease-triggering antibody cross-reactivity.
format Online
Article
Text
id pubmed-8720918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87209182022-01-04 Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens Kasperkiewicz, Michael Bednarek, Marta Tukaj, Stefan Front Med (Lausanne) Medicine It is hypothesized that SARS-CoV-2 has the potential to elicit autoimmunity due to molecular mimicry between immunogenic proteins of the virus and human extracellular molecules. While in silico and in vitro evaluation of such immune cross-reactivity of human antibodies to SARS-CoV-2 proteins with several different tissue antigens has been described, there is limited information specifically pertaining to the immunological effects of COVID-19 and vaccines against SARS-CoV-2 on the development of autoimmune bullous diseases (AIBDs). Twelve seropositive post-COVID-19 individuals and 12 seropositive healthy volunteers who received two doses of the mRNA COVID-19 vaccine from Pfizer-BioNTech have been included in this case series investigation. Serum samples of these blood donors were tested for autoantibodies to the main immunobullous autoantigens, i.e., desmoglein 1, desmoglein 3, envoplakin, BP180, BP230, and type VII collagen. Our study revealed that none of the 24 anti-SARS-CoV-2 IgG-positive subjects had concomitant antibody reactivity with any of the tested autoantigens. These results argue against a relationship between SARS-CoV-2 infection/vaccines and AIBDs with respect to disease-triggering antibody cross-reactivity. Frontiers Media S.A. 2021-12-20 /pmc/articles/PMC8720918/ /pubmed/34988105 http://dx.doi.org/10.3389/fmed.2021.807711 Text en Copyright © 2021 Kasperkiewicz, Bednarek and Tukaj. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kasperkiewicz, Michael
Bednarek, Marta
Tukaj, Stefan
Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
title Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
title_full Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
title_fullStr Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
title_full_unstemmed Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
title_short Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens
title_sort case report: circulating anti-sars-cov-2 antibodies do not cross-react with pemphigus or pemphigoid autoantigens
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720918/
https://www.ncbi.nlm.nih.gov/pubmed/34988105
http://dx.doi.org/10.3389/fmed.2021.807711
work_keys_str_mv AT kasperkiewiczmichael casereportcirculatingantisarscov2antibodiesdonotcrossreactwithpemphigusorpemphigoidautoantigens
AT bednarekmarta casereportcirculatingantisarscov2antibodiesdonotcrossreactwithpemphigusorpemphigoidautoantigens
AT tukajstefan casereportcirculatingantisarscov2antibodiesdonotcrossreactwithpemphigusorpemphigoidautoantigens